GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (STU:6HN) » Definitions » Net Interest Income

Everest Medicines (STU:6HN) Net Interest Income : €8.93 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Everest Medicines Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Everest Medicines's net interest income for the six months ended in Jun. 2024 was €4.38 Mil. Its net interest income for the trailing twelve months (TTM) ended in Jun. 2024 was €8.93 Mil.

Everest Medicines Net Interest Income Historical Data

The historical data trend for Everest Medicines's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Net Interest Income Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Interest Income
Get a 7-Day Free Trial -0.25 -4.00 3.34 4.45 10.87

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.55 2.97 6.34 4.55 4.38

Everest Medicines Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €8.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Net Interest Income Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (STU:6HN) » Definitions » Net Interest Income
Comparable Companies
HKSE:09995 HKSE:06855 HKSE:09969 HKSE:06826 HKSE:01530 HKSE:02696 HKSE:02410 HKSE:02162 HKSE:02171 HKSE:06660 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
01952:Hong Kong 6HN:Germany
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Website
https://www.everestmedicines.com
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Everest Medicines Headlines

No Headlines